Last $109.60 USD
Change Today +3.48 / 3.28%
Volume 6.6M
CELG On Other Exchanges
Symbol
Exchange
NASDAQ GS
Mexico
Frankfurt
NASDAQ GM
As of 5:10 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

86 Morris Avenue

Summit, NJ 07901

United States

Phone: 908-673-9000

Fax: 908-673-9001

apies: At CCT, the company is conducting research with stem cells derived from the human placenta, as well as from the umbilical cord. CCT is the company’s research and development division dedicated to fulfilling the promise of cellular technologies by developing products and therapies to benefit patients. Stem cell based therapies offer the potential to provide disease-modifying outcomes for serious diseases that lack adequate therapy. The company has developed proprietary technology for collecting, processing, and storing placental stem cells with therapeutic applications in cancer, auto-immune diseases, and other inflammatory diseases. The company is developing its cellular therapies, PDA-001 (IV formulation) and PDA-002 (IM/SC injectable formulation), with the initiation of phase I safety and dose finding studies for Crohn’s disease and peripheral arterial diseases. It is also continuing research to define the potential of placental-derived stem cells and to characterize other placental-derived products. CC-486: The company has initiated two phase III trials of CC-486 that are enrolling to evaluate CC-486 in the treatment of MDS and AML. In addition, a phase I trial of CC-486 for the treatment of solid tumors is in progress. Sotatercept (ACE-011) and ACE-536: The company has collaborated with Acceleron Pharma, Inc. (Acceleron) to develop sotatercept and ACE-536 to treat anemia in patients with rare blood disorders. Various phase II trials are in progress to evaluate the use of sotatercept or ACE-536 in the treatment of anemia in patients with rare blood disorders and chronic kidney disease, beta-thalassemia and MDS. mTOR Pathway Inhibitors: CC-223 and CC-115 target the primary cancer pathway that is dysregulated in a proportion of cancers. In particular, activity is being investigated in lymphomas, hepatocellular and prostate cancers in phase I/II trials. Epigenetics: The insights into molecular regulation of genetic information (Epigenetics) have the potential to transform human diseases. Celgene has two epigenetic modifiers on the market, VIDAZA and ISTODAX. In addition, the company is collaborating with Epizyme Inc. (Epizyme) to develop EPZ-5676 for AML. CC-292: CC-292 is in phase I clinical trials for the treatment of CLL and lymphomas. CC-292 is also in phase II combination studies with REVLIMID and Rituxan in CLL’s. Product Development The company’s research and development expenses amounted to $2.226 billion in 2013. Patents and Proprietary Technology The company owns or has licensed 480 issued U.S. patents. In addition, approximately 530 additional pending U.S. patent applications are owned by or exclusively licensed to the company. Patent term extensions have been granted in other markets as well, including Australia and Korea, relative to certain of the company’s patents related to REVLIMID. Patent term extensions relative to lenalidomide have been granted in Japan. Further, patent term extensions relative to ABRAXANE have been secured and/or are actively being sought in Australia, Japan, Russia, and Korea. Significant Events In April 2014, FORMA Therapeutics announced a second strategic collaboration and option agreement with Celgene Corporation. This new collaboration would enable FORMA to extend its unique capabilities across broad areas of chemistry and biology. In April 2014, Forma Therapeutics and Celgene Form Strategic Alliance LENGTH: 764 words Forma Therapeutics, an R&D organization, announced a second strategic collaboration and option agreement with Celgene Corp., a company focusing on addressing unmet medical needs. In June 2014, NantHealth has announced that Celgene Corporation has committed to a strategic $25 million investment in the company. This furthers the ongoing collaboration between the two entities; Celgene invested $75 million in NantBioScience. In August 2014, Bristol-Myers Squibb Company (BMY) and Celgene Corporation (CELG) established a clinical trial collaboration to study a combination regimen of two cancer treatment therapies. In October 2014, Sutro Biopharma entered into a strategic collaboration and option agreement with Celgene

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CELG:US $109.60 USD +3.48

CELG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $66.21 USD +1.86
Biogen Idec Inc $340.89 USD +5.13
Bristol-Myers Squibb Co $59.15 USD -0.01
Eli Lilly & Co $70.16 USD +0.42
Shire PLC 4,470 GBp -63.00
View Industry Companies
 

Industry Analysis

CELG

Industry Average

Valuation CELG Industry Range
Price/Earnings 57.7x
Price/Sales 11.9x
Price/Book 12.9x
Price/Cash Flow 47.0x
TEV/Sales 10.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELGENE CORP, please visit www.celgene.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.